Sialix Inc., a biotechnology company developing cancer immunotherapies, has changed its name to Siamab Therapeutics. The company also has received an additional $2 million in funding as part of its Series B, bringing the total raised to $6 million.
The company's corporate headquarters are in Cambridge, Mass. and its laboratory facilities are in San Diego.
Siamab is developing therapies targeting abnormal carbohydrates present only on cancer cells. Its platform is up and running, and has enabled the discovery and characterization of a panel of anti-TACA therapeutic antibodies for Siamab's first development program ST1.